{"id":3945,"date":"2023-06-04T22:22:34","date_gmt":"2023-06-04T13:22:34","guid":{"rendered":"https:\/\/www.nanomrna.co.jp\/en\/?page_id=3945"},"modified":"2023-07-13T11:37:04","modified_gmt":"2023-07-13T02:37:04","slug":"ent103","status":"publish","type":"page","link":"https:\/\/www.nanomrna.co.jp\/en\/product\/ent103\/","title":{"rendered":"COMLEX&reg;"},"content":{"rendered":"<div class=\"boxInner\">\n<div class=\"flow_con mb30\">\n<h2><span>Co-development with CEOLIA Pharma, a specialty pharmaceutical company in ENT area in Japan<\/span>COMLEX&reg; OTIC SOLUTION 1.5% (Product code: ENT103)<\/h2>\n<p class=\"pgtit_2\">First time in a quarter of a century that a full-scale clinical trial has been conducted in the field of otology<\/p>\n<div class=\"box-two-68 float_l mb20_sp\">\n<p class=\"mb10\">We jointly conducted a full-scale Phase III clinical trial in the otology field for the first clinical trial in a quarter of a century in Japan. We achieved the primary endpoint in September 2021 and obtained approval in Japan for manufacturing and marketing in March 2023.<br \/>Our co-developer, Ceolia Pharma Co., Ltd, markets this pharmaceutical. <\/p>\n<\/div>\n<figure class=\"box-two-25 float_r mb10\">\n<img decoding=\"async\" class=\"imgblock\" src=\"https:\/\/www.nanomrna.co.jp\/en\/nanocms\/wp-content\/themes\/original\/img\/product\/en103.jpg\"><figcaption>Market launch: Jun 8, 2023<\/figcaption><\/figure>\n<\/div>\n<div class=\"btn_2 c_1 pgbtn mb50\">\n<a href=\"https:\/\/www.ceolia.co.jp\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\">CEOLIA Pharma<\/a>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Co-development with CEOLIA Pharma, a specialty pharmaceutical company in ENT area in JapanCOMLEX&reg; OTIC SOL [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3939,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3945"}],"collection":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/comments?post=3945"}],"version-history":[{"count":11,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3945\/revisions"}],"predecessor-version":[{"id":4517,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3945\/revisions\/4517"}],"up":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3939"}],"wp:attachment":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/media?parent=3945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}